

Mixed progress on drug resistance in *A. baumannii* infections in children

May 2 2018

In the first national study of the prevalence of antibiotic-resistant *Acinetobacter baumannii* infections in children across the US, researchers from Center for Disease Dynamics, Economics, & Policy (CDDEP) in Washington, DC and Rush University in Chicago, IL examined national and regional trends of antibiotic resistance in clinical specimens over a 13-year period. While there was an overall increase between 1999 and 2012 in the proportion of isolates of *A. baumannii* that were resistant to cephalosporin and carbapenem, the authors noted a slight decline after a peak in 2008. The decrease may be attributable to a combination of antibiotic stewardship guidelines released in 2007 and infection control guidance specifically designed to combat multi-drug resistant *A. baumannii* in healthcare settings.

Infections caused by drug-susceptible *A. baumannii* are difficult to treat and the emergence of resistance has made treatment even more challenging. Highly resistant *A. baumannii* infections are increasingly being reported worldwide.

The study found that the crude proportion of cephalosporin-resistant *A. baumannii* increased from 13.2% in 1999 to 23.4% in 2012, whereas the proportion of carbapenem-resistant *A. baumannii* increased from 0.6% in 1999 to 6.1% in 2012. From 1999 to 2012, the proportion of cephalosporin-resistant and carbapenem-resistant *A. baumannii* increased each year by 3% and 8%, respectively; however, after 2008, a downward trend was observed, but resistance remained higher than was observed in 1999.

"*Acinetobacter* are bacteria known to cause serious infections that are notoriously difficult to treat because of growing [antibiotic resistance](#)," according to Dr. Latania K. Logan of Rush University Medical Center. "The bacteria survive for long periods in the environment. Further studies are needed to assess the most effective prevention strategies in children, who are particularly vulnerable to *A. baumannii*."

"It is encouraging to see a downtrend after 2008, but we need to continue to monitor [resistance](#) trends," said study co-author Dr. Sumanth Gandra of CDDEP. "The lack of new drugs to treat *Acinetobacter* remains a concern," he said.

More information: Latania K Logan et al, *Acinetobacter baumannii* Resistance Trends in Children in the United States, 1999–2012, *Journal of the Pediatric Infectious Diseases Society* (2018). [DOI: 10.1093/jpids/piy018](#)

Provided by Center for Disease Dynamics, Economics & Policy

Citation: Mixed progress on drug resistance in *A. baumannii* infections in children (2018, May 2) retrieved 3 May 2024 from <https://medicalxpress.com/news/2018-05-drug-resistance-baumannii-infections-children.html>

<p>This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.</p>
--